We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Orthofix Medical Inc. (“Orthofix” or the “Company”) (NASDAQ: OFIX) in connection with the proposed acquisition of the Company by SeaSpine Holdings Corporation (“SeaSpine”) (NASDAQ: SPNE).  Under the terms of the merger agreement, the Company’s shareholders will receive 0.4163 shares of SeaSpine common stock for each Orthofix share owned, representing implied per-share merger consideration of approximately $2.44 based upon SeaSpine’ October 13, 2022 closing price of $5.86.  Upon completion of the transaction, Orthofix shareholders will own approximately 56.5 percent of the combined company, and SeaSpine shareholders will own approximately 43.5 percent of the combined company.

Weiss Law is investigating whether (i) Orthofix’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the per-share merger consideration adequately compensates Orthofix’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.